Myriad Genetics (MYGN) Other financing activities (2010 - 2025)

Myriad Genetics has disclosed Other financing activities across 15 years of filings, most recently posting -$8.6 million for Q4 2025.

• In Q4 2025, Other financing activities fell 2050.0% year-over-year to -$8.6 million; the TTM figure through Dec 2025 stood at -$8.3 million (down 2866.67% YoY), while the FY2025 annual figure was -$200000.0, up 50.0% from the prior year.
• Other financing activities eased to -$8.6 million in Q4 2025, from -$400000.0 in the prior quarter.
• Over the last five years, Other financing activities for MYGN reached as high as $1.2 million in Q1 2021 and fell as low as -$8.6 million in Q4 2025.
• The 4-year median for Other financing activities is $150000.0 (2022), against an average of -$1.8 million.
• The widest YoY moves for Other financing activities: up 2050.0% in 2025, down 2050.0% in 2025.
• A 4-year view of Other financing activities shows it stood at $1.2 million in 2021, then slumped by 41.67% to $700000.0 in 2022, then tumbled by 157.14% to -$400000.0 in 2024, then plunged by 2050.0% to -$8.6 million in 2025.
• According to Business Quant data, Other financing activities over the past three periods registered -$8.6 million, -$400000.0, and $700000.0 for Q4 2025, Q4 2024, and Q3 2022 respectively.